LEADER 01353cam0-2200457---450- 001 990006520210403321 005 20110912114627.0 010 $a88-15-01989-8 035 $a000652021 035 $aFED01000652021 035 $a(Aleph)000652021FED01 035 $a000652021 100 $a20010426d1988----km-y0itay50------ba 101 0 $aita 102 $aIT 105 $aa---i---001yy 200 1 $aElezioni in Italia$estruttura e tipologia delle consultazioni politiche$fPiergiorgio Corbetta, Arturo M.L. Parisi, Hans M.A. Shadee 210 $aBologna$cil Mulino$dc1988 215 $a562 p.$d21 cm 225 1 $aStudi e ricerche$v252 610 0 $aElezioni$aItalia$a1968-1987 676 $a324.6$v19$zita 676 $a19630 676 $aF/1.411 700 1$aCorbetta,$bPiergiorgio$f<1941- >$045919 701 1$aParisi,$bArturo M. L.$f<1940- >$0158198 701 1$aSchadee,$bHans M. A.$0158199 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990006520210403321 952 $aVIII C 15$b1559$fDDCIC 952 $aCOLLEZ. 103 (252)$b6609$fFSPBC 952 $aIX A 857$b26111$fFSPBC 952 $a324.94 COR 1$bDip.d.s.2914$fFLFBC 952 $a19630 ELE$b7232$fSES 959 $aFSPBC 959 $aFLFBC 959 $aSES 959 $aDDCIC 996 $aElezioni in Italia$9620745 997 $aUNINA LEADER 02753nam 2200409 450 001 9910688431903321 005 20230623054846.0 024 7 $a10.17885/heiup.631 035 $a(CKB)5400000000040326 035 $a(NjHacI)995400000000040326 035 $a(EXLCZ)995400000000040326 100 $a20230623d2020 uy 0 101 0 $afre 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aIl Cardinale Pietro Gasparri, segretario di Stato (1914-1930) /$fedited by Laura Pettinaroli, Massimiliano Valente 210 1$aHeidelberg :$cHeidelberg University Publishing (heiUP),$d2020. 210 4$dİ2020 215 $a1 online resource (304 pages) 311 $a3-947732-85-6 320 $aIncludes bibliographical references and index. 330 $aPietro Gasparri (1852-1934) fu un insigne giurista, un apprezzato docente universitario e un abile diplomatico pontificio. Diresse la Segreteria di Stato e la Curia romana dal novembre 1914 al gennaio 1930, cioe? in un periodo cruciale della storia europea e del papato. Il volume - frutto dei seminari di studio sulla "Politica internazionale della Santa Sede" tenuti fra il 2013 e il 2016 e organizzati in collaborazione tra l'Universita? europea di Roma e l'Institut catholique de Paris - presenta i contributi di un gruppo internazionale di storici e archivisti, senior e dottorandi, incentrati su Gasparri nel suo ruolo di segretario di Stato, quale figura centrale del governo della Chiesa cattolica del Novecento. 330 $aPietro Gasparri (1852-1934) was a famous jurist, a valued university professor and an able papal diplomat. He headed the Secretary of State and the Roman Curia from November 1914 to January 1930, during a crucial period in the history of Europe and of the Papacy. This book - the outcome of research seminars on "The international policy of the Holy See" held in Rome between 2013 and 2016 in collaboration with the Universita? europea di Roma and the Institut catholique de Paris - gathers the contributions of an international group of historians and archivists, seniors and PhD students. It focuses on Gasparri in his role as Secretary of State: a central figure of the government of the Church in the twentieth century. 517 $aCardinale Pietro Gasparri, segretario di Stato 606 $aBiography as a literary form 615 0$aBiography as a literary form. 676 $a808.06692 702 $aValente$b Massimiliano 702 $aPettinaroli$b Laura 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910688431903321 996 $aIl Cardinale Pietro Gasparri, segretario di Stato (1914-1930)$93391270 997 $aUNINA LEADER 06995nam 22013213u 450 001 9910808713803321 005 20251116164038.0 010 $a1-283-20363-4 010 $a9786613203632 010 $a0-470-92935-9 010 $a0-470-92934-0 035 $a(CKB)2550000000042753 035 $a(EBL)818637 035 $a(OCoLC)746598445 035 $a(SSID)ssj0000534041 035 $a(PQKBManifestationID)12165841 035 $a(PQKBTitleCode)TC0000534041 035 $a(PQKBWorkID)10493413 035 $a(PQKB)10894419 035 $a(MiAaPQ)EBC818637 035 $a(PPN)190360267 035 $a(EXLCZ)992550000000042753 100 $a20131230d2011|||| u|| | 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAntiviral Drugs $eFrom Basic Discovery Through Clinical Trials 205 $a1st ed. 210 $aHoboken $cWiley$d2011 215 $a1 online resource (470 p.) 300 $aDescription based upon print version of record. 311 08$a1-118-25122-9 311 08$a0-470-45563-2 327 $aANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients 327 $a7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir 327 $a14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection 327 $a21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir 327 $a29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate 330 $aThis book focuses on new small molecule approaches to combat viral infections. The chapters describe the discovery and development from bench through the clinic of relatively recently-approved antiviral drugs and compounds in advanced clinical development. Organized by a virus (such as HIV, HCV, RSV, influenza, HBV and CMV) and written by top academic and industrial authorities in the field, the book provides a unique opportunity to study, understand and apply discovery and development principles and learning without the need for an individual to research, analyze and synthesize all immense so 606 $aAntiviral Agents -- therapeutic use 606 $aAntiviral agents 606 $aClinical Trials as Topic 606 $aDrug Discovery 606 $aDrug Evaluation 606 $aAntiviral agents 606 $aEpidemiologic Studies 606 $aChemistry, Pharmaceutical 606 $aEvaluation Studies as Topic 606 $aInvestigative Techniques 606 $aAnti-Infective Agents 606 $aEpidemiologic Methods 606 $aPharmacology 606 $aTherapeutic Uses 606 $aHealth Care Evaluation Mechanisms 606 $aChemistry 606 $aBiological Science Disciplines 606 $aNatural Science Disciplines 606 $aQuality of Health Care 606 $aPublic Health 606 $aPharmacologic Actions 606 $aEnvironment and Public Health 606 $aHealth Care Quality, Access, and Evaluation 606 $aChemical Actions and Uses 606 $aDelivery of Health Care 606 $aClinical Trials as Topic 606 $aDrug Discovery 606 $aAntiviral Agents 606 $aDrug Evaluation 606 $aHealth & Biological Sciences$2HILCC 606 $aPharmacy, Therapeutics, & Pharmacology$2HILCC 615 4$aAntiviral Agents -- therapeutic use. 615 4$aAntiviral agents. 615 4$aClinical Trials as Topic. 615 4$aDrug Discovery. 615 4$aDrug Evaluation. 615 0$aAntiviral agents. 615 2$aEpidemiologic Studies. 615 2$aChemistry, Pharmaceutical. 615 2$aEvaluation Studies as Topic. 615 2$aInvestigative Techniques. 615 2$aAnti-Infective Agents. 615 2$aEpidemiologic Methods. 615 2$aPharmacology. 615 2$aTherapeutic Uses. 615 2$aHealth Care Evaluation Mechanisms. 615 2$aChemistry. 615 2$aBiological Science Disciplines. 615 2$aNatural Science Disciplines. 615 2$aQuality of Health Care. 615 2$aPublic Health. 615 2$aPharmacologic Actions. 615 2$aEnvironment and Public Health. 615 2$aHealth Care Quality, Access, and Evaluation. 615 2$aChemical Actions and Uses. 615 2$aDelivery of Health Care. 615 2$aClinical Trials as Topic. 615 2$aDrug Discovery. 615 2$aAntiviral Agents. 615 2$aDrug Evaluation. 615 7$aHealth & Biological Sciences 615 7$aPharmacy, Therapeutics, & Pharmacology 676 $a615/.7924 700 $aKazmierski$b Wieslaw M$01671234 702 $aKazmierski$b Wieslaw M. 801 0$bAU-PeEL 801 1$bAU-PeEL 801 2$bAU-PeEL 906 $aBOOK 912 $a9910808713803321 996 $aAntiviral Drugs$94033635 997 $aUNINA